|1.||Pritchett, Edward L C: 9 articles (02/2008 - 04/2002)|
|2.||Pratt, Craig M: 8 articles (09/2008 - 09/2003)|
|3.||Al-Khalidi, Hussein R: 7 articles (09/2008 - 03/2004)|
|4.||Wilkinson, William E: 7 articles (02/2008 - 04/2002)|
|5.||Page, Richard L: 7 articles (02/2008 - 04/2002)|
|6.||Marcello, Stephen R: 7 articles (08/2006 - 04/2002)|
|7.||Holroyde, Michael J: 6 articles (09/2008 - 03/2004)|
|8.||Brum, Jose M: 6 articles (09/2008 - 04/2004)|
|9.||Dorian, Paul: 5 articles (09/2008 - 12/2004)|
|10.||Connolly, Stuart J: 5 articles (07/2006 - 04/2002)|
04/07/2004 - "The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial."
05/01/2006 - "Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. "
03/04/2003 - "In the 3 trials evaluating azimilide in therapeutic doses (100 and 125 mg), asymptomatic atrial fibrillation occurred in 49 of 382 (13%) receiving azimilide and 43 of 233 (18%) receiving placebo. "
04/01/2002 - "In Phase I clinical pharmacology studies, azimilide was associated with prolongation of the QT and QTc intervals on electrocardiograms recorded during sinus rhythm in normal subjects, but the effect of azimilide on the target population of patients with atrial fibrillation has not been reported in detail previously. "
11/01/2007 - "Effects of azimilide on experimental atrial fibrillation (AF) were also examined in isolated guinea-pig hearts. "
09/01/2001 - "Azimilide prevented VF initiation by programmed electrical stimulation by causing conduction block of reentrant impulses in the EBZ during the initial beats of rapid polymorphic ventricular tachycardia, despite the reverse use-dependent effects on ERP. "
12/01/1993 - "As compared with predrug incidence (12 of 12), NE-10064 (10 mg/kg intravenously, i.v.) reduced (p < 0.05) the incidence (8 of 12) of PES-induced ventricular tachycardia (VT). "
12/01/2006 - "This study is a prospectively designed secondary analysis of SHIELD; a randomized trial of azimilide for suppression of ventricular tachycardia/fibrillation (VT/VF) leading to implanted cardioverter defibrillator (ICD) therapies. "
01/01/2005 - "Azimilide was not associated with a significant reduction in shocks, but reduced the shocks or episodes of markedly symptomatic ventricular tachycardia terminated by pacing in the SHIELD (Shock Inhibition Evaluation with Azimilide) study. "
12/01/1993 - "Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug."
|3.||Atrial Flutter (Flutter, Atrial)
07/01/1996 - "In a functional model of circus movement atrial flutter, azimilide dihydrochloride terminates and prevents reinduction of atrial flutter by a preferential increase in refractoriness leading to further conduction delay and conduction block in the slow zone of the functional reentrant circuit."
07/01/1996 - "At 3 mg/kg, azimilide dihydrochloride terminated atrial flutter in 2 dogs; however, atrial flutter was reinduced. "
07/01/1996 - "Doses of 3, 10, and 30 mg/kg i.v. azimilide dihydrochloride were analyzed in 8 dogs in which sustained atrial flutter lasting more than 30 minutes was induced by burst pacing. "
03/04/2003 - "Patients in sinus rhythm with a history of symptomatic atrial fibrillation or atrial flutter received placebo or azimilide (35 to 125 mg) once daily for 6 or 9 months in 4 similar double-blind trials. "
04/01/2002 - "The purpose of this study was to assess the effect of azimilide, a Class III antiarrhythmic drug, on ECG conduction intervals recorded during sinus rhythm in patients with a history of symptomatic atrial fibrillation or atrial flutter. "
05/01/1999 - "Both preclinical and clinical studies have demonstrated the efficacy of azimilide and its safety in the management of supraventricular and ventricular tachyarrhythmia. "
12/14/2004 - "A total of 633 ICD recipients were enrolled in a randomized, double-blind, placebo-controlled study to evaluate the effect of daily doses of 75 or 125 mg of azimilide on recurrent symptomatic ventricular tachyarrhythmias and ICD therapies. "
02/01/2005 - "Azimilide is an investigational Class III antiarrhythmic that has been developed for treating both supraventricular and ventricular tachyarrhythmias. "
12/14/2004 - "Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator."
01/07/2004 - "Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators."
|5.||Heart Diseases (Heart Disease)
07/15/2006 - "Nonsignificant trends were seen toward efficacy of azimilide in the CHF/CHD group (hazard ratio 1.28, 95% confidence interval 0.97 to 1.70, p=0.087), structural heart disease group (hazard ratio 1.22, 95% confidence interval 0.96 to 1.56, p=0.11), and overall group (hazard ratio 1.22, 95% confidence interval 1.00 to 1.49, p=0.053). "
07/15/2006 - "Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease."
03/19/1998 - "Azimilide has a good safety profile in open-label safety studies in >800 supraventricular arrhythmia patients, most with structural heart disease. "
05/01/2006 - "Azimilide did not demonstrate clinically important or statistically significant efficacy in reducing the risk for arrhythmia recurrence in patients with structural heart disease who were in atrial fibrillation and converted to sinus rhythm."
02/01/2005 - "Clinically, in a series of 4 double-blind, randomized, placebo-controlled trials, the Azimilide Supraventricular Arrhythmia Program which included over 1000 patients and approximately 70% with structural heart disease, azimilide showed a significant prolongation in the time to first recurrence of paroxysmal supraventricular tachycardia or atrial fibrillation/flutter. "
|1.||Sotalol (Sotalol Hydrochloride)
|5.||Adenosine Triphosphate (ATP)
|1.||Electric Countershock (Cardioversion)
|2.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)